To date no definite and undisputed treatment has been found for sickle cell anemia, which is characterized by polymerization of a deoxygenated hemoglobin mutant (HbS) giving rise to deformed erythrocytes and vasoocclusive complications. Since the erythrocyte glycerate 2,3-bisphosphate (2,3-DPG) has been shown to facilitate this polymerization, one therapeutic approach would be to decrease the intraerythrocytic level of 2,3-DPG by increasing the phosphatase activity of the bisphosphoglycerate mutase (BPGM; 3-phospho-Dglycerate 1,2-phosphomutase, EC 5.4.2.4). For this purpose, we have investigated the role of Gly-13, which is located in the active site sequence Arg'-His"'-Gly"1-Glu12-Gly13 in human BPGM. This sequence is similar to the Arg-His-Gly-Xaa-Arg* sequence of the distantly related acid phosphatases, which catalyze as BPGM similar phosphoryl transfers but to a greater extent. We hypothesized that the conserved Arg* residue in acid phosphatase sequences facilitates the phosphoryl transfer. Consequently, in human BPGM, we replaced by site-directed mutagenesis the corresponding amino acid residue Gly'3 with an Arg or a Lys. In another experiment, we replaced Gly'3 with Ser, the amino acid present at the corresponding position of the homologous yeast phosphoglycerate mutase (n-phosphoglycerate 2,3-phosphomutase, EC 5.4.2.1). Mutation of Gly'3 to Ser did not modify the synthase activity, whereas the mutase and the phosphatase were 2-fold increased or decreased, respectively. However, replacing Gly'3 with Arg enhanced phosphatase activity 28.6-fold, whereas synthase and mutase activities were 10-fold decreased. The presence of a Lys in position 13 gave rise to a smaller increase in phosphatase activity (6.5-fold) but an identical decrease in synthase and mutase activities. Taken together these results support the hypothesis that a positively charged amino acid residue in position 13, especially Arg, greatly activates the phosphoryl transfer to water. These results also provide elements for locating the conserved Arg* residue in the active site of acid phosphatases and facilitating the phosphoryl transfer. The implications for genetic therapy of sickle cell disease are discussed.
ABSTRACT
To date no definite and undisputed treatment has been found for sickle cell anemia, which is characterized by polymerization of a deoxygenated hemoglobin mutant (HbS) giving rise to deformed erythrocytes and vasoocclusive complications. Since the erythrocyte glycerate 2,3-bisphosphate (2,3-DPG) has been shown to facilitate this polymerization, one therapeutic approach would be to decrease the intraerythrocytic level of 2,3-DPG by increasing the phosphatase activity of the bisphosphoglycerate mutase (BPGM; 3-phospho-Dglycerate 1,2-phosphomutase, EC 5.4.2.4). For this purpose, we have investigated the role of Gly-13, which is located in the active site sequence Arg'-His"'-Gly"1-Glu12-Gly13 in human BPGM. This sequence is similar to the Arg-His-Gly-Xaa-Arg* sequence of the distantly related acid phosphatases, which catalyze as BPGM similar phosphoryl transfers but to a greater extent. We hypothesized that the conserved Arg* residue in acid phosphatase sequences facilitates the phosphoryl transfer. Consequently, in human BPGM, we replaced by site-directed mutagenesis the corresponding amino acid residue Gly'3 with an Arg or a Lys. In another experiment, we replaced Gly'3 with Ser, the amino acid present at the corresponding position of the homologous yeast phosphoglycerate mutase (n-phosphoglycerate 2,3-phosphomutase, EC 5.4.2.1). Mutation of Gly'3 to Ser did not modify the synthase activity, whereas the mutase and the phosphatase were 2-fold increased or decreased, respectively. However, replacing Gly'3 with Arg enhanced phosphatase activity 28.6-fold, whereas synthase and mutase activities were 10-fold decreased. The presence of a Lys in position 13 gave rise to a smaller increase in phosphatase activity (6.5-fold) but an identical decrease in synthase and mutase activities. Taken together these results support the hypothesis that a positively charged amino acid residue in position 13, especially Arg, greatly activates the phosphoryl transfer to water. These results also provide elements for locating the conserved Arg* residue in the active site of acid phosphatases and facilitating the phosphoryl transfer. The implications for genetic therapy of sickle cell disease are discussed.
Some enzymes displaying phosphatase activities such as human prostatic acid phosphatase (1, 2), lysosomal (3) and yeast (4) acid phosphatases, erythrocyte bisphosphoglycerate mutase (BPGM; 3-phospho-D-glycerate 1,2-phosphomutase, EC 5.4.2.4) (5-7), glycolytic phosphoglycerate mutase (PGM; D-phosphoglycerate 2,3-phosphomutase, EC 5.4.2.1) (7, 8) , and hepatic 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (fructose-2,6-bisphosphate 2-phosphatase; D-fructose-2,6-bisphosphate 2-phosphohydrolase, EC 3.1.3.46) (1) possess a His residue in their active site, which is transiently phosphorylated during the course of the phosphoryl transfer. It was suggested that most such enzymes involved in the binding of phosphate esters should have at least one cationic group suitably disposed near the active site His in order to facilitate the orientation and binding of the phosphate group and consequently activate the phosphoryl transfer to water (2) .
Little is known about the three-dimensional structure and particularly localization of the active site residues in acid phosphatases. Conversely, the structure of the yeast PGM has been determined by x-ray diffraction analysis by using crystals soaked in 3-phosphoglycerate (3-PG). This latter enzyme shares 5Ow sequence identity with human BPGM and catalyzes the same three reactions (synthase, mutase, and phosphatase), although at substantially different rates. These activities are catalyzed at the unique active site of BPGM. To date and in spite of recent crystallization of human BPGM (9) , no crystallographic data have been obtained for this enzyme. Consequently, the amino acids involved in the active site of human BPGM have been deduced by comparison with the structure of the yeast PGM (8) . Amino acid residues of the active site were highly conserved between BPGM and PGM. The different catalytic rates observed for these two homologous enzymes could be explained by the nonconserved residues in their active site. Among them, Gly13 in BPGM and the homologous Ser11 in the yeast PGM have been postulated to play an important role (7, 8) .
Synthase and phosphatase activities of BPGM catalyze, respectively, the synthesis and degradation of glycerate 2,3-bisphosphate (2,3-DPG), the main allosteric effector of hemoglobin. In spite of the presence of acid phosphatases in erythrocytes, the degradation of2,3-DPG is very low because these acid phosphatases cannot degrade 2,3-DPG and the phosphatase activity of BPGM is very slow (1000-fold lower than the synthase activity and lower than that of acid phosphatases). Consequently, 2,3-DPG is present in high concentrations in erythrocytes.
Our purpose being to decrease 2,3-DPG level in erythrocytes by increasing the BPGM phosphatase activity, we have compared amino acid sequences of several acid phosphatases possessing a His residue in their active site and especially the sequences of a fragment common to these enzymes and human BPGM (Fig. 1) (4) . This fragment, corresponding to the amino acid sequence Arg9-His10-Gly11-Glu12-Gly13 in human BPGM, is homologous to the amino acid sequence Arg7-His8-Gly9-Gln10-Ser'1 in yeast PGM, which is localized in the active site and contains the phosphorylatable His (7, 8, 10) . 
deprived of 2,3-DPG. In the case of 2-phosphoglycolate hepatic 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase (Fstimulation of the phosphatase reaction, 1 mM 2-phospho-2,6-P2ase), human prostatic acid phosphatase (Hu-P-ACP), human glycolate was added to the standard assay system and belysosomal acid phosphatase (Hu-L-ACP), yeast acid phosphatase P1
cause of its potent effect (19) (11) . Oligonucleotides were synthesized by the phoszymes was performed using the UNIX version of the BRUGEL phoramidite method on an Applied Biosystems DNA synsoftware package as described (10) . Modeling of the threethesizer (model 381A) followed by purification by electrodimensional conformation of the human BPGM enzyme was phoresis on a 20%6 polyacrylamide gel containing 7 M urea. made by using the known crystallographic structure of the Site-Directed Mutagenesis. The procedure used for oligohomologous yeast PGM as a starting structure (8) . nucleotide-directed site-specific mutagenesis was based on the method described by Taylor et al. (12) phages were prepared and sequenced by the dideoxynucleof the cDNA was sequenced by using specific internal otide cham-termination method (13) to confirm the desired oligonucleotides in order to confirm that no additional mumutation. The complete sequence of the mutated BPGM tation was introduced during mutagenesis. insert was then checked entirely between the restriction sites Large amounts of the wild type and the three mutants of used for subcloning in the expression vector pKK223-3 human BPGM (Gly13 to Arg, Gly13 to Lys, and Gly13 to Ser) (Pharmacia) as described (14) . For all these procedures, the were expressed in E. coli by using the expression vector basic cloning methods described by Maniatis et al. were used pKK223-3 as described for the wild-type human BPGM (14) .
(15).
Each BPGM variant and the wild-type enzyme were proPreparation of Overexpressed Mutants and Wild-Type Huduced in E. coli in the same amount (-5.5% of the bacterial man BPGM. Overnight cultures of Escherichia coli containprotein). As demonstrated for the wild-type enzyme, the ing an expression plasmid of either mutant or wild-type growth rate of bacteria was decreased every time 2,3-DPG enzyme were grown in L broth medium containing ampicillin was synthesized by the recombinant enzyme (14) . Such an (100 ug/ml) and then diluted 1:100 for the expression culinhibition of the growth rate of bacteria was not observed tures. Induction of protein expression was performed with during expression of the Gly13 to Arg and Gly13 to Lys isopropyl /3-D-thiogalactoside as described (14) .
variants, which produced very low levels of 2,3-DPG as Purification of the mutant and wild-type enzymes was described below. In contrast, this inhibition was similar to performed as described (16) (12) has the sequence 5'-CATGGAGAGCGTGCTTGAATT-3'. Construction of the expression vector, expression of the wild-type and mutant BPGM, and their purification have been described (14, 16) . Induction of the tac promoter of the expression vector was made with 0.5 mM isopropyl f-D-thiogalactoside during 3 h at 37°C.
Neither synthase activity nor detectable amounts of 2,3-DPG could be found in crude extracts of nontransformed E. coli XL1-B bacteria. Consequently, we measured these values in the lysate of the bacteria expressing the different recombinant enzymes. When bacteria expressed the Gly13 to Arg and Gly13 to Lys variants, we detected a low synthase activity (0.038 and 0.11 unit per mg of protein, respectively) as well as a low 2,3-DPG production (0.0016 and 0.0015 umol of 2,3-DPG per mg of protein, respectively). In contrast, a synthase activity (0.41 unit per mg of protein) similar to that obtained with the wild-type enzyme (0.45 unit per mg of protein) was present in the crude extracts of E. coli transformed with the plasmid bearing the Gly13 to Ser mutation, giving rise to production of 0.027 ,umol of 2,3-DPG per mg of protein (control, 0.054 umol of 2,3-DPG per mg of protein).
All the variants were purified to homogeneity (14, 16) . A single polypeptide band with a molecular mass of 30 kDa was obtained by SDS/PAGE for each purified enzyme after Coomassie blue staining as shown in Fig. 2 for the Gly13 to Arg variant. All the variants were stable when incubated at 55°C for 30 min.
Catalytic Properties of Gly'3 Variants. The catalytic properties of the three variants are summarized in Table 1 and compared to those of normal human BPGM expressed in E. coli. When Gly'3 was replaced by Ser, a slight decrease (2-fold) of the phosphatase activity was observed and there was a lower capacity of its stimulation by 2-phosphoglycolate. Simultaneously the synthase activity was normal and the mutase activity was 2-fold increased. By contrast, when Arg or Lys replaced Glyl3 a very strong increase in the phosphatase activity (28.6-and 6.5-fold, respectively) was observed, whereas phosphatase stimulation by 2-phosphoglycolate was decreased. These two variants (Glyl3 to Arg and Glyl3 to Lys) showed decreased synthase (10-and 8.6-fold, respectively) and mutase (10-and 6.4-fold, respectively) activities. It should be noted that the control values of the phosphatase activities and Km values were different from those previously reported (16) because of the differences in the two assay techniques.
The Michaelis constants for the substrates in the three reactions catalyzed by wild-type and mutant human BPGM were measured (16) and are summarized in Table 2 . The Km for 3-PG in the synthase activity and for 2-PG in the mutase activity were slightly modified (2-fold).
The Michaelis constants for the binding of 2,3-DPG were 2-to 6.7-fold decreased in the basic phosphatase activity and the mutase activity of the three variants except for a slight increase in the mutase activity for the Gly'3 to Arg variant. In contrast, a moderate increase was observed for the Gly13 to Arg and Gly13 to Lys variants in the 2-phosphoglycolatestimulated phosphatase activity (3.5-and 2.5-fold, respectively). The Km value for the 1,3-DPG in the synthase activity could not be determined because of the great instability of this substrate.
DISCUSSION
In this report, we show that replacement by site-directed mutagenesis of Glyl3 by Ser in human BPGM did not greatly modify the catalytic properties of the mutant enzyme as compared to the wild-type BPGM. The slightly decreased phosphatase activities as well as increased mutase activity mimic the PGM enzyme, and these results are in accord with those obtained for the corresponding yeast PGM Ser" to Gly variant recently produced by White and Fothergill-Gilmore (23) (as shown in Fig. 1 In conclusion, if the peptide that has a sequence similar to that of BPGM performs a similar function in all the acid phosphatases, it is reasonable to assume that, as in BPGM, it contains the active site (phospho)His residue and that the conserved Arg* residue is located in their active site. In addition, it is likely that activation of the phosphoryl transfer to a water molecule obtained in this report for human BPGM with the Gly'3 to Arg mutation is not unique to this enzyme but represents a common mechanism for other phosphatases possessing His residues in their active site. It would be interesting to make the corresponding mutation in the yeast PGM (7) and fructose-2,6-bisphosphatase (1) to show that such a mutation also activates the phosphatase activity.
Only in vitro modulation of 2,3-DPG level has been performed to study its effect on polymerization of deoxyHbS (24) . The recent production by several laboratories (25) (26) (27) and ourselves (28) of a transgenic mouse model of sickle cell disease (29) (30) (31) (32) (33) offers the opportunity to evaluate the potential role of a decreased 2,3-DPG level in vivo on erythrocyte sickling by expressing the Gly'3 to Arg BPGM variant in their sickle erythrocytes.
